Change In Sales Plan For Amitiza Highlights Mallinckrodt's Strengthening Generics Business
Pharma & Healthcare / United Kingdom / Tue 04 Jun, 2019
Key View
- This amendment to Mallinckrodt's business separation plans highlights improving fortunes for its Specialty Generics segment.
- Increasing revenues from sales of Amitiza will help to bolster the Specialty Brands segment, which remains the larger of the two segments, but which has seen revenues falter in recent quarters.
- The Specialty